The Relationship between Inflammation Markers (CRP, IL-6, sCD40L) and Colorectal Cancer Stage, Grade, Size and Location

The aim of the study was the evaluation whether in primary colorectal cancer (CRC) patients (n = 55): age, sex, TNM classification results, WHO grade, tumor location (proximal colon, distal colon, rectum), tumor size, platelet count (PLT), mean platelet volume (MPV), mean platelet component (MCP), levels of carcinoembryonic antigen (CEA), cancer antigen (CA 19-9), as well as soluble lectin adhesion molecules (L-, E-, and P-selectins) may influence circulating inflammatory biomarkers: IL-6, CRP, and sCD40L. We found that CRP concentration evaluation in routine clinical practice may have an advantage as a prognostic biomarker in CRC patients, as this protein the most comprehensively reflects clinicopathological features of the tumor. Univariate linear regression analysis revealed that in CRC patients: (1) with an increase in PLT by 10 × 103/μL, the mean concentration of CRP increases by 3.4%; (2) with an increase in CA 19-9 of 1 U/mL, the mean concentration of CRP increases by 0.7%; (3) with the WHO 2 grade, the mean CRP concentration increases 3.631 times relative to the WHO 1 grade group; (4) with the WHO 3 grade, the mean CRP concentration increases by 4.916 times relative to the WHO 1 grade group; (5) with metastases (T1-4N+M+) the mean CRP concentration increases 4.183 times compared to non-metastatic patients (T1-4N0M0); (6) with a tumor located in the proximal colon, the mean concentration of CRP increases 2.175 times compared to a tumor located in the distal colon; (7) in patients with tumor size > 3 cm, the CRP concentration is about 2 times higher than in patients with tumor size ≤ 3 cm. In the multivariate linear regression model, the variables that influence the mean CRP value in CRC patients included: WHO grade and tumor localization. R2 for the created model equals 0.50, which indicates that this model explains 50% of the variance in the dependent variable. In CRC subjects: (1) with the WHO 2 grade, the mean CRP concentration rises 3.924 times relative to the WHO 1 grade; (2) with the WHO 3 grade, the mean CRP concentration increases 4.721 times in relation to the WHO 1 grade; (3) with a tumor located in the rectum, the mean CRP concentration rises 2.139 times compared to a tumor located in the distal colon; (4) with a tumor located in the proximal colon, the mean concentration of CRP increases 1.998 times compared to the tumor located in the distal colon; if other model parameters are fixed.

[1]  M. Maciejczyk,et al.  Antioxidant Barrier, Redox Status, and Oxidative Damage to Biomolecules in Patients with Colorectal Cancer. Can Malondialdehyde and Catalase Be Markers of Colorectal Cancer Advancement? , 2019, Biomolecules.

[2]  A. Milewska,et al.  Serum and cerebrospinal fluid Neudesin concentration and Neudesin Quotient as potential circulating biomarkers of a primary brain tumor , 2019, BMC Cancer.

[3]  S. Ryu,et al.  Mechanisms regulating intestinal barrier integrity and its pathological implications , 2018, Experimental & Molecular Medicine.

[4]  Y. Fujiwara,et al.  Prognostic value of the combination of pre- and postoperative C-reactive protein in colorectal cancer patients , 2018, Surgery Today.

[5]  Christian Dehlendorff,et al.  Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer , 2018, Oncotarget.

[6]  Jun Shen,et al.  IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. , 2017, Biochemical and biophysical research communications.

[7]  M. Antonelli,et al.  It's time to redefine inflammation , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  J. Kamińska,et al.  Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines. , 2016, Polskie Archiwum Medycyny Wewnetrznej.

[9]  W. Chou,et al.  Pretreatment serum interleukin‐1β, interleukin‐6, and tumor necrosis factor‐α levels predict the progression of colorectal cancer , 2016, Cancer medicine.

[10]  Hiroki Takahashi,et al.  Preoperative Serum Interleukin-6 Is a Potential Prognostic Factor for Colorectal Cancer, including Stage II Patients , 2015, Gastroenterology research and practice.

[11]  E. Giovannucci,et al.  Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women , 2015, Cancer Prevention Research.

[12]  Bernard Klein,et al.  Interleukin-6 as a Therapeutic Target , 2015, Clinical Cancer Research.

[13]  S. Pathak,et al.  Is C‐reactive protein useful in prognostication for colorectal cancer? A systematic review , 2014, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[14]  Toshio Tanaka,et al.  IL-6 in inflammation, immunity, and disease. , 2014, Cold Spring Harbor perspectives in biology.

[15]  H. Kemona,et al.  Multifunctional CD40L: pro- and anti-neoplastic activity , 2014, Tumor Biology.

[16]  H. Kemona,et al.  Potential Role of Soluble CD40 Ligand as Inflammatory Biomarker in Colorectal Cancer Patients , 2014, The International journal of biological markers.

[17]  Mikinori Sato,et al.  Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction , 2013, British Journal of Cancer.

[18]  M. Choti,et al.  Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[19]  J. Schlom,et al.  Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. , 2012, Blood.

[20]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[21]  Yongling Ning,et al.  Role of vascular endothelial growth factor receptor in the pro-proliferation activity of CD40-CD40L in AGS gastric cancer cells , 2010 .

[22]  Y. DeClerck,et al.  Interleukin-6 in bone metastasis and cancer progression. , 2010, European journal of cancer.

[23]  Z. Culig,et al.  Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells , 2010, Endocrine-related cancer.

[24]  M. Matłok,et al.  IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[25]  C. Hua,et al.  Expression of CD40 and CD40L in Gastric Cancer Tissue and Its Clinical Significance , 2009, International journal of molecular sciences.

[26]  Chia-Siu Wang,et al.  C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. , 2009, Chang Gung medical journal.

[27]  P. Dunbar,et al.  Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). , 2009, Neoplasia.

[28]  P. Kosmidis,et al.  Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. , 2009, Anticancer research.

[29]  Byung Geun Kim,et al.  Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer , 2009, BMC Cancer.

[30]  R. Noelle,et al.  Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.

[31]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[32]  M. Karin,et al.  Autocrine IL-6 signaling: a key event in tumorigenesis? , 2008, Cancer cell.

[33]  A. Melcher,et al.  CD40‐mediated death and cytokine secretion in colorectal cancer: A potential target for inflammatory tumour cell killing , 2007, International journal of cancer.

[34]  D. Lawlor,et al.  A systematic review of the association between circulating concentrations of C reactive protein and cancer , 2007, Journal of Epidemiology and Community Health.

[35]  H. Kemona,et al.  Does surgery affect certain mediators of thrombocytopoiesis in patients with colorectal cancer? , 2007, Hepato-gastroenterology.

[36]  Chekhun Vf,et al.  Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. , 2007 .

[37]  D. Frank,et al.  IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor. , 2004, Carcinogenesis.

[38]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[39]  M. Sans,et al.  The CD40/CD40L costimulatory pathway in inflammatory bowel disease , 2004, Gut.

[40]  N. Konishi,et al.  C-Reactive Protein as a Prognostic Variable That Reflects Uncontrolled Up-Regulation of the IL-1-IL-6 Network System in Colorectal Carcinoma , 2004, Digestive Diseases and Sciences.

[41]  G. Davı̀,et al.  Soluble CD40 Ligand Plasma Levels in Lung Cancer , 2004, Clinical Cancer Research.

[42]  C. McArdle,et al.  Systemic inflammatory response predicts survival following curative resection of colorectal cancer , 2003, The British journal of surgery.

[43]  T. Sieber,et al.  Increased expression of CD40 ligand on activated T cells of patients with colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  L. Pelosio,et al.  Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. , 2002, Clinical immunology.

[45]  T. Nozoe,et al.  Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. , 2000, American journal of clinical oncology.

[46]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[47]  P. Libby,et al.  Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? , 1997, Circulation research.

[48]  P. Thompson,et al.  ACSM's Guidelines for Exercise Testing and Prescription , 1995 .

[49]  S. Ishihara,et al.  Changes in the plasma levels of cytokines/chemokines for predicting the response to chemoradiation therapy in rectal cancer patients. , 2014, Oncology reports.

[50]  R. Küppers Molecular biology of Hodgkin lymphoma. , 2009, Hematology. American Society of Hematology. Education Program.

[51]  H. Kemona,et al.  Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. , 2007, Thrombosis research.

[52]  A. Caro-Patón Gómez,et al.  Interleukins and colon cancer. , 2005, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[53]  MariaGazouli,et al.  Serum IL-6, TNFα and CRP levels in Greek colorectal cancer patients: Prognostic implications , 2005 .